Join us   Log in   pharmaspire@isfcp.org  


PHARMASPIRE - Volume 15, Issue 01,2023 , Jan-March

Pages: 22-27
Print Article   Download XML  Download PDF

An insight into the mucormycosis: “The black fungus” mutilating COVID-19 patients

Author: Debajyoti Roy, Seema Brar, Naresh Kumar Rangra

Category: Pharmacognosy

Abstract:

COVID-19-associated mucormycosis (CAM) is an uncommon but possibly lethal fungal illness that has surfaced as a possible COVID-19 consequence. The infection is caused by a Mucorales family fungus that is often found in the environment. COVID-19 individuals who have uncontrolled diabetes, long-term steroid use, or mechanical ventilation are at a higher risk of developing mucormycosis. Mucormycosis can be ophthalmic, gastrointestinal, sinus orbital, cutaneous, or pulmonary, with symptoms differing depending on the kind and site of the infection. The epidemiology of CAM is unknown, but there have been reports of a rise in the prevalence in some parts of the world, including India and Iran. Herbal treatment has been proposed as an adjunctive treatment to conventional treatment, but further studies are required to assess its efficacy. Early detection and treatment are essential to enhancing patient outcomes, and health-care practitioners should be mindful of the risk factors for CAM. Further research is needed to better comprehend the pathophysiology, epidemiology, and management of this newly discovered fungal infection.

Keywords: Causes of mucormycosis, COVID-19-associated mucormycosis, Symptoms of mucormycosis, Treatment of mucormycosis, Types of mucormycosis

DOI: 10.56933/Pharmaspire.2023.15104

DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15104

References:

1. Pushparaj K, Bhotla HK, Arumugam VA, Pappusamy M, Easwaran M, Liu WC, et al. Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets-Magnifying global pandemic grieve and catastrophe begins. Sci Total Environ 2022;805:150355.
2. Kumar KR. Mucormycosis: A black fungus-post covid complications. J Regen Biol Med 2021;3:1-8.
3. Chakrabarti A, Dhaliwal M. Epidemiology of mucormycosis in India. Curr Fungal Infect Rep 2013;7:287-92.
4. Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new? J Diabetes Res Clin Pract 2020;167:108383.
5. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi (Basel) 2021;7:298.
6. Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Gilani A, et al. Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance. MedRxiv; 2021.
7. Tay MZ, Poh CM, Re?nia L, MacAry PA, Ng LF. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363-74.
8. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, et al. Mucormycosis in renal transplant recipients: Review of 174 reported cases. BMC Infect Dis 2017;17:283.
9. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia 2020;185:599-606.
10. Garg PK, Gupta N, Gautam V, Hadke NS. Gastric zygomycosis: Unusual cause of gastric perforation in an immunocompetent patient. South Med J 2008;101:449-50.
11. De Moura DT, Proença IM, McCarty T.R, Sagae VM, Ribeiro IB, de Oliveira G, et al. Gastrointestinal manifestations and associated health outcomes of covid-19: A Brazilian experience from the largest South American public hospital. Clinics (Sao Paulo)
2020;75:e2271.
12. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr., Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis 2009;48:1743-51.
13. Zia Q, Azhar A, Kamal MA, Aliev G, Owais M, Ashraf GM. Super aggregated form of Amphotericin B: A novel way to increase its therapeutic index. Curr Pharm Des 2016;22:792-803.
14. Chen Z, Wherry EJ. T cell responses in patients with COVID-19. Nat Rev Immunol 2020;20:529-36.
15. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54:S23-34.
16. Hosseini SM, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol
2005;262:932-8.
17. Franquet T, Giménez A, Hidalgo A. Imaging of opportunistic fungal infections in immunocompromised patient. Eur J Radiol 2004;51:130-8.
18. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
19. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17:1859-67.
20. Hampson FG, Ridgway EJ, Feeley K, Reilly JT. A fatal case of disseminated zygomycosis associated with the use of blood glucose self-monitoring equipment. J Infect 2005;51:e269-72.
21. Hocker TL, Wada DA, Bridges A, el-Azhary R. Disseminated zygomycosis heralded by a subtle cutaneous finding. Dermatol Online J 2010;16:3.
22. Kordy FN, Al-Mohsen IZ, Hashem F, Almodovar E, Al Hajjar S, Walsh TJ. Successful treatment of a child with posttraumatic necrotizing fasciitis caused by Apophysomyces elegans: Case report and review of literature. Pediatr Infect Dis J 2004;23:877-9.
23. Kerr OA, Bong C, Wallis C, Tidman MJ. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol 2004;150:1212-3.
24. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-50.
25. Gupta KL, Khullar DK, Behera D, Radotra BD, Sakhuja V. Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 1998;13:3258-60.
26. Kitabayashi A, Hirokawa M, Yamaguchi A, Takatsu H, Miura AB. Invasive pulmonary mucormycosis with rupture of the thoracic aorta. Am J Hematol 1998;58:326-9.

27. Passamonte PM, Dix JD. Nosocomial pulmonary mucormycosis with fatal massive hemoptysis. Am J Med Sci 1985;289:65-7.
28. Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest 1979;75:524-6.
29. Hsu JW, Chiang CD. A case report of novel roentgenographic finding in pulmonary zygomycosis: Thickening of the posterior tracheal band. Kaohsiung J Med Sci 1996;12:595-600.
30. Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health 2022;15:466-79.
31. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries. Lancet Microbe 2022;3:e543-52.
32. Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H, et al. Global prevalence of COVID-19- associated mucormycosis (CAM): Living systematic review and meta-analysis. J Fungi (Basel) 2021;7:985.
33. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146.
34. Sarda R, Swain S, Ray A, Wig N. COVID-19-associated mucormycosis: An epidemic within a pandemic. QJM 2021;114:355-6.
35. Ministry of AYUSH Govt. of India, Guidelines for Ayurveda Practitioner’s for Covid-19. Available from: https://bit.ly/3DunVzH [Last accessed on 2023 Apr 20].
36. Mohsina FP, Faheem IP, Tabassum S, Shah I, Ahmad A. An insight of mucormycosis (black fungus) in ayurveda. Open J Pharmacol Pharmacotherapeut 2021;6:13-7.